NKGen Biotech Inc. Common... (NKGN)
0.16
-0.01 (-3.09%)
At close: Mar 25, 2025, 3:36 PM
0.16
0.00%
After-hours: Mar 25, 2025, 03:36 PM EDT
-3.09% (1D)
| Bid | 0.16 |
| Market Cap | 7.08M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -75.35M |
| EPS (ttm) | -2.27 |
| PE Ratio (ttm) | -0.07 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 0.17 |
| Volume | 56,519 |
| Avg. Volume (20D) | 4,019,540 |
| Open | 0.16 |
| Previous Close | 0.17 |
| Day's Range | 0.15 - 0.17 |
| 52-Week Range | 0.10 - 2.19 |
| Beta | 0.45 |
About NKGN
Graf Acquisition Corp. IV does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. Graf Acquisition Corp. IV was incorporated in 2021 and is based in The Woodlands, Texas....
Industry Biotechnology
Sector Healthcare
IPO Date Oct 2, 2023
Employees 63
Stock Exchange NASDAQ
Ticker Symbol NKGN
Website https://www.grafacq.com
1 month ago
+27.12%
NKGen Biotech shares are trading higher after the ...
Unlock content with
Pro Subscription
1 month ago
+121.64%
NKGen Biotech shares are trading higher after the company received FDA Fast Track designation for Troculeucel for the treatment of moderate Alzheimer's disease.
